Reactions 1680, p113 - 2 Dec 2017 ★ S First report of pulmonary oedema: case report In a retrospective study of 126 patients, a patient was described [age and sex not stated], who developed pulmonary oedema following treatment with daratumumab. The patient, who had a history of multiple myeloma, was started on IV infusion of daratumumab 16 mg/kg body weight weekly for the first eight weeks, every two weeks for the next 16 weeks and then monthly. Following daratumumab infusion, the patient developed pulmonary oedema, which required non-invasive mechanical ventilation [time to reaction onset and outcome not stated]. Author comment: "One patient developed pulmonary edema following daratumumab infusion and required noninvasive mechanical ventilation." Lakshman A, et al. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. American Journal of Hematology 92: 1146-1155, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1002/ajh.24883 - USA 803284996 » Editorial comment: A search of AdisBase, Medline and Embase did not reveal any previous case reports of pulmonary oedema associated with daratumumab. The WHO ADR database contained 5 reports of pulmonary oedema associated with 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera